Clinical Trials Logo

Clinical Trial Summary

find the role of alpha one microglobulin (as an early renal tubular biomarker) to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV and compared these patients with HCV-negative healthy individuals


Clinical Trial Description

Hepatitis C [HCV] infection is known to cause renal manifestations, which are discovered at a late stage when chronic kidney disease (CKD) has already occurred . HCV is both a consequence and cause of renal impairment: first, dialysis patients have an increased risk of infection related to medical procedures and, second, HCV causes pathological changes to the kidneys . HCV seems to influence both renal tubular and glomerular cells as described by different proteinuria profiles and hematuria findings. Tubular cell damage may be the earliest sign of renal dysfunction caused by HCV and could potentially be used to identify patients with risk for progression. Routine urine analysis could be used to identify high risk HCV patients for early treatment. Identifying patients early is of paramount importance in order to offer a prompt intervention and to improve the prognosis in both settings, for this purposes, novel biomarkers could be used One promising biomarker is alpha-1-microglobulin (α1m), a low molecular weight glycosylated protein of molecular weight synthesized by hepatocytes, freely filtered across the glomerulus, and then reabsorbed by the proximal tubule . it can signal proximal tubule dysfunction: higher Uα1m concentrations indicate impaired tubular reabsorption . Small studies have previously shown that Uα1m concentrations increase in Acute kidney injury (AKI), reflect severity of AKI, and are associated with the need for dialysis after nonoliguric AKI . Elevated Uα1m correlates with interstitial fibrosis and tubular atrophy on kidney biopsy, representing chronic kidney damage . Furthermore, Uα1m appears to predict kidney function decline and CKD progression , Acute kidney injury risk and also associated with early tubulointerstitial renal diseases in HCV-glomerulopathy . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05276700
Study type Observational
Source Assiut University
Contact Ghada Safwat, master
Phone 01288348166
Email ghadasafwat1714@gmail.com
Status Not yet recruiting
Phase
Start date July 15, 2022
Completion date March 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05942937 - National Prisons Hepatitis Education Project: Research Evaluation N/A
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Recruiting NCT05794646 - Community Intervention to Eliminate HCV Among People Who Use Drugs. N/A
Completed NCT04971330 - Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A
Recruiting NCT03981445 - Integrated HIV Prevention and HCV Care for PWID N/A
Completed NCT02452814 - Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection N/A
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Not yet recruiting NCT06316739 - The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City N/A
Completed NCT02116543 - TD-6450 MAD Study in HCV Infected Subjects Phase 1
Recruiting NCT05454579 - The South-East Asian Transgender Health Cohort
Active, not recruiting NCT03221309 - Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Completed NCT03801707 - Utilization of Hepatitis C Positive Kidneys in Negative Recipients Phase 2/Phase 3
Not yet recruiting NCT03820102 - Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
Completed NCT01074008 - A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Phase 2
Completed NCT05616598 - Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Phase 2/Phase 3
Recruiting NCT05854511 - Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Phase 3
Completed NCT03069001 - Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV Phase 4